NCT01419431

Brief Summary

Pro-inflammatory responses following laparoscopic surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2007

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
4.5 years until next milestone

First Submitted

Initial submission to the registry

July 18, 2011

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 18, 2011

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

December 16, 2011

Status Verified

December 1, 2011

Enrollment Period

4.8 years

First QC Date

July 18, 2011

Last Update Submit

December 15, 2011

Conditions

Regulation of Inflammatory Response

Keywords

Colon cancer

Outcome Measures

Primary Outcomes (1)

  • Inflammatory values for laparoscopic resection for colon cancer.

    Corresponding values of SOCS3 mRNA copared to inflammatory cytokines in patients with laparoscopic resection for colon cancer.

    3 days

Study Arms (1)

Colon cancer patients

Laparoscopic resection

Procedure: Laparoscopic resection

Interventions

Laparoscopic resectionPROCEDURE

Inflammatory response in laparoscopic surgery

Also known as: Colon cancer
Colon cancer patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Colon cancer stage I-III

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oslo University Hospital

Oslo, 0407, Norway

Location

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Study Officials

  • Dag T. Førland, MD

    OUS

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

July 18, 2011

First Posted

August 18, 2011

Study Start

January 1, 2007

Primary Completion

November 1, 2011

Study Completion

December 1, 2011

Last Updated

December 16, 2011

Record last verified: 2011-12

Locations

NO(1)